Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 1013-1019

  He, Qimin ^a   Zhang, Pinggn ^b   Zou, Li ^b   Li, Hongxun ^c   Wang, Xiuqin ^c   Zhou, Shan ^b   Fornander, Tommy ^a   Skog, Sven ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b WUHAN UNIVERSITY   (China)

^c HUBEI CANCER HOSPITAL   (China)

Author keywords

Human tumors; S TK1; Serum thymidine kinase 1; Tumor markers

Indexed keywords

THYMIDINE KINASE; THYMIDINE KINASE 1; TUMOR MARKER;

ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; CELL PROLIFERATION; DOSE RESPONSE; FEMALE; HUMAN; MALE; METHODOLOGY; NEOPLASM; PATHOLOGY; RADIOIMMUNOASSAY; STOMACH TUMOR; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS; RADIOIMMUNOASSAY; STOMACH NEOPLASMS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644831355     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.1013     Document Type: Article

References (22)

1. Wu JP, Mao YR, He LX, Wang N, Wu C J, He Q and Skog S: A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 20: 4815-4820, 2000. (Pubitemid 32127735)
2. Mao YR, Wu JP, Wang N, He LX, Wu C J, He Q and Skog S: A comparison study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 20: 922-931, 2002. (Pubitemid 35315926)
3. He Q, Mao YR, Wu YP, Decker C, Merza M, Wang N, Eriksson S, Castro J and Skog S: The cytosolic thymidine kinase tumor marker is more specific for ductal infiltrated breast cacinomas of histopathologic grade 2 than Ki-67. Int J Oncol 25: 945-953, 2004.
4. Mao YR, Wu JP, Skog S, Eriksson S, Zhao YW, Zhou J and He Q: Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep 13: 837-846, 2005.
5. Wang N and Tribukait B: Proliferation activity in carcinoma and intraepithelial neoplasia of prostate as assessed by expression of thymidine kinase 1 and Ki-67, and by DNA cytometry. In: Quantitative Cellular Methods in the Evaluation of Prostate Cancer. Wang N (ed). ISBN 91-628-3929-2, VII, pp1-18, 2000.
6. Gronowitz JS, Hagberg H, Källander CFR and Simonsson B: The use of serum deoxythymidine kinase as a prognostic marker in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47: 487-495, 1983. (Pubitemid 13089615)
7. Gronowitz JS, Källander CFR, Diderholm H, Hagberg H and Pettersson U: Application of an in vivo assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 15: 5-12, 1984. (Pubitemid 14223226)
8. Hallek M, Wanders L, Strohmeyer S and Emmerich B: Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5, 1995.
9. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E and Emmerich B: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia. Blood 93: 1732-1737, 1999. (Pubitemid 29102502)
10. Broët P, Romain S, Daver A, Ricollean G, Quillen V, Rallet A, Asslain B, Martin PM, Foekens JA, Romain S, Look MP, Martin PM and Klijn GM: Thymidine kinase and thymidylate synthaseb in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1412-1425, 2001.
11. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H and Miki T: Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma. J Urol 171: 605-610, 2004. (Pubitemid 38090440)
12. Kok M, Bonfrer JM, Korse CM, De Jong D and Kersten MJ: Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 24: 53-60, 2003. (Pubitemid 36578819)
13. Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1421-1425, 2001. (Pubitemid 34292567)
14. He Q, Zou L, Zhang PG, Liu J, Skog S and Fonander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. J Biol Marker 15: 139-146, 2000. (Pubitemid 30389361)
15. Zou L, Zhang PG, Zou S, Li Y and He Q: The half-life of cytosolic thymidine kinase in serum by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. J Biol Marker 17: 135-140, 2002. (Pubitemid 34873800)
16. Li HX, Zhang S, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep 13: 145-149, 2005.
17. He Q, Wang N, Skog S, Ericsson S and Tribukait B: Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70: 117-124, 1996. (Pubitemid 26177210)
18. Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H and Miyazaki K: Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology 61: 47-54, 2001. (Pubitemid 32727587)
19. Wang N, He Q, Skog S, Eriksson S and Tribukait B: Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 23: 11-19, 2001. (Pubitemid 34014656)
20. Nicolini A, Carpi A, Ferrari P and Pieri L: Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumor Biol 24: 275-280, 2003. (Pubitemid 38327988)
21. Zhang F, Li H, Pendleton AR, Robinson JG, Monson KO, Murray BK and O'Neill KL: Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev 25: 8-15, 2001.
22. Kuroiwa N, Nakayama M, Fufuda T, Fufui H, Ohwada H, Hiwasa T and Fujimura S: Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibody raised against recombinant human thymidine kinase. J Immunol Methods 253: 1 -11, 2001.